4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Stroke Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Stroke by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 532 ongoing clinical trials involving Stroke
Of the 532 trials,163 trials are in Phase II
Furthermore, 149 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Stroke by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Stroke, a Cardiovascular condition. The largest number of ongoing clinical trials for Stroke is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Stroke-related drug trials.

General Hospital of Shenyang Military Region: The leading ongoing Stroke related clinical trial sponsor

General Hospital of Shenyang Military Region is the top sponsor for Stroke-related ongoing clinical trials.

Beijing Tiantan Hospital Capital Medical University, Zhejiang University School of Medicine Hospital 2, Dongzhimen Hospital, Yonsei University, and Beijing University of Chinese Medicine are among other notable clinical trial sponsors involved in Stroke. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Stroke

Apixaban (Eliquis), Rivaroxaban (Xarelto), and Dulaglutide (Trulicity) are key marketed drugs involving Stroke.

Apixaban (Eliquis) is a phenylpiperidine derivative, acts as an antithrombotic or anticoagulant agent. It functions via Coagulation Factor X Inhibitor mechanism of action. It is formulated as tablets and film-coated tablets for the oral route of administration. Eliquis is indicated to reduce the risk of stroke, systemic embolism in patients with nonvalvular atrial fibrillation and for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery, treatment, and prevention of the recurrence of venous thromboembolism. Apixaban was first approved in 2011 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Bristol-Myers Squibb Co.

Rivaroxaban (Xarelto) belongs to the class of antithrombotic agents. It functions via Coagulation Factor X Inhibitor mechanism of action. It is formulated as film-coated tablets, tablets, granules/powder for suspension, and suspension for oral route of administration. Xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery. Rivaroxaban was first approved in 2008 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Janssen Pharmaceuticals Inc.

Explore the latest trends and actionable insights on the Stroke Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Stroke Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store